Biocon Appoints Peter Bains as Group CEO to Drive Growth and Synergy

Bengaluru, India – September 18, 2023: Biocon Ltd , a globally renowned biopharmaceuticals company known for its innovation-driven approach, has made a significant announcement. The company's Board of Directors has unanimously approved the appointment of Peter Bains as the Group CEO, effective as of September 18th, 2023. Mr. Bains will report directly to Biocon Group Chairperson, Kiran Mazumdar-Shaw.

This strategic appointment has been made with the aim of ushering Biocon into a dynamic phase of growth for its three core businesses, namely Biocon Biologics, Biocon Generics, and Syngene. Bains brings to the table extensive global leadership experience and a track record of success within the biopharmaceutical industry.

To assume his new role as Group CEO,  Bains has promptly resigned from his position as an Independent Director on the Biocon Board. This transition marks a significant step in the company's journey towards optimizing synergies and maximizing the combined value of all three businesses.

In welcoming Mr. Bains to this pivotal role, Kiran Mazumdar-Shaw expressed her enthusiasm: "Biocon is entering a dynamic phase of growth for its 3 core businesses, and for the Group as a whole. I am delighted to welcome Peter back to the Biocon Group in the role of Group CEO."

The existing CEOs and Managing Directors of Biocon Ltd, Biocon Biologics Ltd, and Syngene International Ltd (Siddharth Mittal, Shreehas Tambe, and Jonathan Hunt, respectively) will continue to oversee their businesses independently. This collaborative approach is expected to strengthen strategic leadership at a Group level, further aligning the interests of all stakeholders.

Peter Bains is no stranger to the Biocon Group. He previously led Syngene for five years, overseeing its highly successful IPO in 2015. This experience, coupled with his global leadership acumen, makes him an ideal fit for the role of Group CEO.

Kiran Mazumdar-Shaw expressed her confidence in the appointment, emphasizing its potential to serve the integrated business objectives of the Biocon Group and deliver added value to all stakeholders.